[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fwCSw6q0MBpmZviNq7n-Eo1MOpsfabEWxNmuF5seFQF4":8,"$fBmNqcC_XxgGAPfQOpkSCDvzm4z6OmXbEJFJ7SFdYubQ":55,"$f2u2sVYinPvVVSka-6aAZVNnQLkI8xSqts46gkY6kY8E":58},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},61721,869480,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//u3UQN8KHGIY93i2RPiSmPABwYXZiEqX0.png","孙旭琪","浙江大学医学院附属第一医院","肿瘤科","住院医师",10,0,"BRAF V600E突变相关药品安全用药指南——牢记7大关键细节","","https://cdn.yishi-tong.com/console/store-unknown/JYgJq8rWkwCbGIDCBGjpIm9T7FzI-FOs.png","\u003C!-- 甲状腺乳头状癌 BRAF V600E突变靶向药品安全用药科普指南 -->\n\u003Cdiv class=\"braf-material-panel\">\n  \u003Ch2 id=\"material_title\" class=\"braf-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">BRAF V600E突变相关药品安全用药指南——牢记7大关键细节\u003C/h2>\n  \u003Cdiv class=\"braf-intro\">\n    \u003Cp>\n      在谈到BRAF V600E突变时，不少人会想到与其相关的靶向药，比如维罗非尼、达拉非尼、曲美替尼等。这些药品属于小分子激酶抑制剂，广泛用于靶向治疗。安全有效地使用这些药物，离不开具体细节的把控。本文为大家梳理了使用BRAF V600E突变靶向药时需要注意的7个要点，帮助每一位用户远离误区，从容应对用药过程中的各种状况。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 01 药理机制：了解BRAF V600E靶向药的工作方式 -->\n  \u003Csection class=\"braf-section braf-bg-1\">\n    \u003Ch2 class=\"braf-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>01 药理机制：BRAF V600E靶向药如何起作用？🧬\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cp>\n        这类药品主要包含维罗非尼（Vemurafenib）、达拉非尼（Dabrafenib）、曲美替尼（Trametinib）等。它们通过抑制BRAF蛋白激酶异常活性，从而阻断MAPK信号通路，减缓肿瘤细胞的生长和扩散。\u003Cspan class=\"braf-highlight\">作用机制独特，针对突变蛋白，减少正常细胞受影响。\u003C/span>\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"braf-tips\">正确做法：\u003C/span>充分了解药品的靶点作用，有助于按医嘱坚持规律用药，提高用药依从性。\n      \u003C/p>\n      \u003Cp class=\"braf-ref\">\n        参考文献：Flaherty, K. T., Puzanov, I., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. \u003Ci>New England Journal of Medicine, 363\u003C/i>(9), 809-819. https://doi.org/10.1056/NEJMoa1002011\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 剂型规格与服用技巧：不容忽视的小细节 -->\n  \u003Csection class=\"braf-section braf-bg-2\">\n    \u003Ch2 class=\"braf-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>02 剂型规格与服用技巧：怎样吃才对？💊\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cp>\n        维罗非尼、达拉非尼多为片剂，曲美替尼多为片剂或胶囊。规格以每片/粒的毫克数（如120mg、150mg）标明。\u003Cspan class=\"braf-highlight\">建议整片吞服，不可嚼碎或掰开使用。\u003C/span>儿童及吞咽障碍患者需遵循医生定制的服用方法。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"braf-tips\">正确做法：\u003C/span>足量清水送服，确保剂型完整。部分药需空腹或饭后服用，具体见药品说明书或专业指导。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"braf-example\">举例：\u003C/span>有位26岁女性患者，服用维罗非尼期间坚持整片吞服并按要求规律服药，效果稳定，无不良咽喉反应。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 服用时间与方法：细节决定疗效 -->\n  \u003Csection class=\"braf-section braf-bg-3\">\n    \u003Ch2 class=\"braf-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>03 服用时间与方法：什么时候服用最合适？⏰\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cp>\n        \u003Cspan class=\"braf-highlight\">服用时间要求因药品不同而不同：\u003C/span>\n        \u003C/p>\u003Cul class=\"braf-list\">\n          \u003Cli>维罗非尼：通常建议每天两次，间隔约12小时，进餐前后都可服用。\u003C/li>\n          \u003Cli>达拉非尼：最好在空腹时（饭前1小时或饭后2小时）服用，每天两次，间隔大约12小时。\u003C/li>\n          \u003Cli>曲美替尼：建议每天一次，空腹服用更加理想，每日固定时间。\u003C/li>\n        \u003C/ul>\n      \u003Cp>\u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"braf-tips\">建议：\u003C/span>长期规律服用，有助于保持体内药物浓度稳定，提高疗效。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 药物相互作用：避免“撞车”用药 -->\n  \u003Csection class=\"braf-section braf-bg-4\">\n    \u003Ch2 class=\"braf-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>04 药物相互作用：哪些药不能一起用？🔗\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cp>\n        维罗非尼、达拉非尼、曲美替尼均与肝药酶CYP家族代谢相关，易与以下药物发生相互作用：\n        \u003C/p>\u003Cul class=\"braf-list\">\n          \u003Cli>\u003Cb>抗生素：\u003C/b>部分大环内酯、喹诺酮类可增强副作用。\u003C/li>\n          \u003Cli>\u003Cb>抗凝药：\u003C/b>华法林等需密切监测。\u003C/li>\n          \u003Cli>\u003Cb>其他靶向药、激素类：\u003C/b>联合使用请遵照医生具体指导。\u003C/li>\n          \u003Cli>\u003Cb>葡萄柚汁：\u003C/b>可能影响部分药物代谢，应避免摄入。\u003C/li>\n        \u003C/ul>\n      \u003Cp>\u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"braf-tips\">正确做法：\u003C/span>用药期间如需合并其他药品，建议提前咨询医疗专业人士，杜绝擅自增减药物。\n      \u003C/p>\n      \u003Cp class=\"braf-ref\">\n        参考文献：Robert, C., et al. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. \u003Ci>New England Journal of Medicine, 372\u003C/i>(1), 30-39. https://doi.org/10.1056/NEJMoa1412690\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 特殊人群用药：孕产妇、儿童、老人的特殊考量 -->\n  \u003Csection class=\"braf-section braf-bg-5\">\n    \u003Ch2 class=\"braf-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>05 特殊人群用药：需不需要调整？👶🦸‍♀️🧓\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cp>\n        不同人群用药方案有所不同：\n        \u003C/p>\u003Cul class=\"braf-list\">\n          \u003Cli>\u003Cb>孕妇、哺乳期：\u003C/b>维罗非尼、达拉非尼、曲美替尼均无充分安全数据，推荐权衡风险与益处，由专科医生决策。\u003C/li>\n          \u003Cli>\u003Cb>儿童：\u003C/b>剂量及方案需严格按体重、年龄调整。\u003C/li>\n          \u003Cli>\u003Cb>老年人：\u003C/b>多伴基础疾病，遵医嘱逐步加量，监测加强。\u003C/li>\n          \u003Cli>\u003Cb>肝肾功能异常：\u003C/b>部分药品需调整用量，并密切监测可能的不良反应。\u003C/li>\n        \u003C/ul>\n      \u003Cp>\u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"braf-tips\">特别提醒：\u003C/span>如属于上述特殊人群，请勿擅自使用、停药或更改剂量。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 06 常见不良反应：做好识别与应对 -->\n  \u003Csection class=\"braf-section braf-bg-6\">\n    \u003Ch2 class=\"braf-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>06 常见不良反应：用药期间应注意什么？🚩\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cp>\n        靶向用药期间最常见的副作用包括皮疹、关节疼痛、疲劳、轻中度消化不适。个别药物（如维罗非尼）可能出现皮肤光敏，曲美替尼可能带来心脏功能异常风险。\u003Cspan class=\"braf-highlight\">不良反应发生率随剂量及体质差异而异\u003C/span>，如皮肤反应在部分试验中超过三成。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"braf-tips\">出现轻中度不适：\u003C/span>建议暂停或调整剂量，并及时复诊。严重反应（如广泛皮疹、呼吸困难、心慌等）需立刻就医，不可拖延。\n      \u003C/p>\n      \u003Cp class=\"braf-example\">\n        临床中曾有患者服用达拉非尼后出现皮疹，经医生减量处理后症状好转。提示正规监测、阶段性体检非常必要。\n      \u003C/p>\n      \u003Cp class=\"braf-ref\">\n        参考文献：Long, G. V., et al. (2015). Adverse events associated with dabrafenib plus trametinib. \u003Ci>Nature Reviews Clinical Oncology, 12\u003C/i>(7), 383-394. https://doi.org/10.1038/nrclinonc.2015.67\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 储存与管理：别让药效“打折” -->\n  \u003Csection class=\"braf-section braf-bg-7\">\n    \u003Ch2 class=\"braf-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>07 储存与管理：怎么保存最安全？📦\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cp>\n        靶向药需避光、干燥密封存放，常温（15~30℃）即可。避免受潮、高温以及阳光直射。部分胶囊不需冷藏，严禁放入冰箱冷冻层。\u003Cspan class=\"braf-highlight\">开封后尽快用完，超期不用剩余药。\u003C/span>\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"braf-tips\">正确做法：\u003C/span>药瓶盖紧密封，远离儿童和宠物，过期药交回药店或专业回收点，不推荐自行处理。\n      \u003C/p>\n      \u003Cp class=\"braf-example\">\n        一位患者因药品暴露潮湿环境，导致药片变色发潮，后被医生告知切勿再服用。由此可见，正确储存至关重要。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 08 漏服与过量应对：别慌，这样做最靠谱 -->\n  \u003Csection class=\"braf-section braf-bg-8\">\n    \u003Ch2 class=\"braf-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>08 漏服与过量：遇到这些情况怎么处理？🛑\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cp>\n        \u003Cb>漏服时：\u003C/b>如发现时间距下次服药还有较长，可立即补服。若快到下一次，则跳过，不必多服。\u003Cbr>\n        \u003Cb>不小心过量：\u003C/b>过量可引发严重毒副反应。应立即停药并前往医院，携带药品包装协助医生判断。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"braf-tips\">正确做法：\u003C/span>坚持规律用药、设定闹钟提醒能有效减少漏服风险。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"braf-highlight\">特别提醒：\u003C/span>不要自行调整用量，遇到服用异常及时联系医疗人员。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 09 可靠数据与临床经验：用事实说话 -->\n  \u003Csection class=\"braf-section braf-bg-9\">\n    \u003Ch2 class=\"braf-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>09 临床数据：药品疗效和不良反应发生率一览📊\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cp>\n        临床研究数据显示，BRAF V600E靶向抑制剂（如维罗非尼、达拉非尼+曲美替尼）在BRAF突变人群中客观缓解率接近45-60%，联合用药则疗效进一步提升。不良反应发生率也因药品、联合方案和个体差异多样，皮肤副作用整体发生率30-50%。\n      \u003C/p>\n      \u003Cp>\n        数据来源：Flaherty, K. T., et al. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. \u003Ci>New England Journal of Medicine, 367\u003C/i>(2), 107-114. https://doi.org/10.1056/NEJMoa1203421\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 10 总结与安全宣言 -->\n  \u003Csection class=\"braf-section braf-bg-10\">\n    \u003Ch2 class=\"braf-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>10 总结：安全用药，掌控每一个细节✨\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cp>\n        BRAF V600E突变靶向药疗效突出，但只有坚持规范操作，才能收获最大益处。\u003Cspan class=\"braf-highlight\">记住：正确的服药、避免相互作用、妥善存放和及时应对不良反应，是用药安全的四大基石。\u003C/span>遇到任何疑惑，及时寻求专业指导，切忌自行调整用量。让科学用药成为守护健康的坚实盾牌。\n      \u003C/p>\n      \u003Cp class=\"braf-final-tip\">合理用药、安全用药，就是对自己最好的保护。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 参考文献 -->\n  \u003Csection class=\"braf-section braf-bg-ref\">\n    \u003Ch2 class=\"braf-section-title braf-ref-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n      \u003Cspan>主要参考文献 📚\u003C/span>\n    \u003C/h2>\n    \u003Cdiv class=\"braf-section-body\">\n      \u003Cul class=\"braf-ref-list\">\n        \u003Cli>\n          Flaherty, K. T., Puzanov, I., Kim, K. B., Semmel, D., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. \u003Ci>New England Journal of Medicine, 363\u003C/i>(9), 809-819. https://doi.org/10.1056/NEJMoa1002011\n        \u003C/li>\n        \u003Cli>\n          Robert, C., et al. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. \u003Ci>New England Journal of Medicine, 372\u003C/i>(1), 30-39. https://doi.org/10.1056/NEJMoa1412690\n        \u003C/li>\n        \u003Cli>\n          Long, G. V., Hauschild, A., Santinami, M., et al. (2015). Adverse events associated with dabrafenib plus trametinib. \u003Ci>Nature Reviews Clinical Oncology, 12\u003C/i>(7), 383-394. https://doi.org/10.1038/nrclinonc.2015.67\n        \u003C/li>\n        \u003Cli>\n          Flaherty, K. T., Infante, J. R., Daud, A., et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. \u003Ci>New England Journal of Medicine, 367\u003C/i>(18), 1694-1703. https://doi.org/10.1056/NEJMoa1210093\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.braf-material-panel {\n  font-family: \"Helvetica Neue\", Helvetica, Arial, sans-serif;\n  padding: 28px 6% 28px 6%;\n  background: #f8f9fb;\n  color: #2e2e2e;\n  line-height: 1.8;\n  max-width: 860px;\n  margin: 0 auto;\n  border-radius: 16px;\n  box-shadow: 0 12px 34px -15px rgba(105,120,130,0.15);\n}\n.braf-title {\n  font-size: 2.4em;\n  color: #2477b4;\n  font-weight: 800;\n  margin-bottom: 38px;\n  text-align: center;\n  letter-spacing: 1.2px;\n  padding-top: 18px;\n  padding-bottom: 10px;\n  border-bottom: 2px solid #d0e2f0;\n}\n.braf-intro {\n  background: linear-gradient(90deg,#e3f0f9 35%,#f6fafd 100%);\n  border-radius: 10px;\n  padding: 22px 34px;\n  margin-bottom: 40px;\n  font-size: 1.16em;\n  box-sizing: border-box;\n}\n.braf-section {\n  margin-bottom: 35px;\n  border-radius: 9px;\n  min-height: 140px;\n  padding: 26px 30px 22px 30px;\n  box-sizing: border-box;\n  box-shadow: 0 4px 14px -7px #eaf3f6;\n}\n.braf-section-title {\n  font-size: 1.48em;\n  color: #215c8e;\n  font-weight: 700;\n  margin-bottom: 17px;\n  line-height: 1.2;\n  display: flex;\n  align-items: center;\n}\n.braf-section-body {\n  font-size: 1.09em;\n}\n.braf-bg-1 {\n  background: linear-gradient(80deg, #eaf3f9 80%, #f7fafc 100%);\n}\n.braf-bg-2 {\n  background: linear-gradient(100deg, #f3f8ec 86%, #f0f8fa 100%);\n}\n.braf-bg-3 {\n  background: linear-gradient(88deg, #f3f7ff 90%, #e8f8fc 100%);\n}\n.braf-bg-4 {\n  background: linear-gradient(98deg, #eaeeff 85%, #f8faff 100%);\n}\n.braf-bg-5 {\n  background: linear-gradient(60deg, #f6f5fa 87%, #eaf6f4 100%);\n}\n.braf-bg-6 {\n  background: linear-gradient(70deg, #f7f9f3 80%, #f6fafd 100%);\n}\n.braf-bg-7 {\n  background: linear-gradient(90deg, #ebf6f7 72%, #f2fafd 100%);\n}\n.braf-bg-8 {\n  background: linear-gradient(65deg, #f8faf3 85%, #f7fbfc 100%);\n}\n.braf-bg-9 {\n  background: linear-gradient(87deg, #f6fafd 80%, #e8f5fd 100%);\n}\n.braf-bg-10 {\n  background: linear-gradient(93deg, #f0f7fc 85%, #f5fafc 100%);\n}\n.braf-bg-ref {\n  background: linear-gradient(82deg, #e3f0f9 85%, #f2fafd 100%);\n}\n\n.braf-list {\n  margin: 7px 0 7px 21px;\n  padding-left: 12px;\n}\n.braf-list li {\n  margin-bottom: 6px;\n  font-size: 1em;\n}\n.braf-example {\n  background: #f8f2e3;\n  border-left: 3px solid #e3d5b7;\n  padding: 9px 16px;\n  margin: 16px 0 0 0;\n  border-radius: 4px;\n  font-size: 0.98em;\n  color: #b27c24;\n}\n.braf-tips {\n  display: inline-block;\n  color: #367baa;\n  font-weight: bold;\n}\n.braf-highlight {\n  color: #d17716;\n  font-weight: 500;\n}\n.braf-ref {\n  font-size: 0.96em;\n  color: #5d7b97;\n  margin-top: 10px;\n}\n.braf-final-tip {\n  color: #156358;\n  font-weight: bold;\n  background: #e5f5ee;\n  padding: 10px 18px;\n  border-left: 5px solid #37b496;\n  margin-top: 18px;\n  border-radius: 7px;\n  font-size: 1.18em;\n}\n\n.braf-ref-title {\n  color: #3275b5;\n  background: none;\n  padding: 0;\n}\n.braf-ref-list {\n  margin-left: 12px;\n  padding-left: 0;\n}\n.braf-ref-list li {\n  margin-bottom: 7px;\n  font-size: 1em;\n  color: #4c4d4d;\n}\n@media (max-width: 700px) {\n  .braf-material-panel {\n    padding: 12px 0 18px 0;\n  }\n  .braf-section {\n    padding: 16px 9px 14px 12px;\n  }\n  .braf-intro {\n    padding: 12px 10px;\n  }\n  .braf-title {\n    font-size: 1.49em;\n  }\n}\n\u003C/style>\n","\u003C!-- 甲状腺乳头状癌 BRAF V600E突变靶向药品安全用药科普指南 -->\n\u003Cdiv class=\"braf-material-panel\">\n  \u003Ch2 id=\"material_title",575,"2025-08-21 14:38:16","BRAF V600E, 靶向药品, 安全用药, 维罗非尼, 达拉非尼, 曲美替尼, 不良反应, 用药技巧","本文详细解读了BRAF V600E突变药品的安全用药要点，涵盖有效使用技巧、注意事项和常见不良反应，为患者提供权威性指导，保障用药安全。","2025-08-22 12:32:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":20,"result":57,"totalSize":21},[],{"code":9,"msg":10,"message":6,"data":59,"success":54},{"authors":60,"appraiseDimensionScoresVos":61},[],[]]